Meredith Nicholas, Harp Jordan, McLouth Christopher J, Frank Jacqueline A, Cranford Will, Al-Kawaz Mais N, Pahwa Shivani, Trout Amanda L, Stowe Ann M, Dornbos David L, Fraser Justin F, Pennypacker Keith R
College of Medicine, University of Kentucky, Lexington, KY, USA.
Department of Neurology, University of Kentucky, Lexington, KY, USA.
Transl Stroke Res. 2025 Apr 23. doi: 10.1007/s12975-025-01353-1.
Rates of recurrent strokes have remained relatively unchanged over the past couple decades, highlighting a need for advancements in secondary prevention of stroke recurrence. This study utilizes the Blood And Clot Thrombectomy Registry And Collaboration (BACTRAC) tissue bank to identify proteomic and demographic differences in recurrent ischemic stroke patients. Blood samples were collected during mechanical thrombectomy of large-vessel occlusion ischemic strokes. Plasma levels for 184 inflammatory and cardiometabolic proteins were measured in systemic blood and intracranial blood from the infarction area. Differences between recurrent and first-stroke patients were analyzed using Fisher's Exact Test for categorical variables and Student's independent samples t tests or Welch's t tests for continuous variables. Proteins were divided into systemic and intracranial proteins, and independent samples t tests were performed with a False Discovery Rate of 5.0%. Significant variables were used in multiple logistic regression. There were 20 patients in the prior stroke group and 121 in the first stroke group. The prior stroke group had a significantly higher percentage of females (80.0% vs 50.4%, p = 0.016) and lower rate of hyperlipidemia comorbidity (10.5% vs 35.5%, p = 0.034). Two systemic proteins were significantly higher in those with a prior stroke: CCL14 and FGF-19. Multiple logistic regression found higher levels of CCL14 and FGF-19 to be predictive of a stroke being recurrent. Along with other demographics, these proteins could provide a predictive model to identify patients with risk of recurrent ischemic strokes. Serum CCL14 and FGF-19 levels are easily accessible biomarkers, making them possible therapeutic targets for recurrent stroke prevention.
在过去几十年中,复发性中风的发生率相对保持不变,这凸显了在中风复发二级预防方面取得进展的必要性。本研究利用血液与血栓切除术登记与协作组织(BACTRAC)的组织库来确定复发性缺血性中风患者的蛋白质组学和人口统计学差异。在大血管闭塞性缺血性中风的机械取栓过程中采集血样。对梗死区域全身血液和颅内血液中184种炎症和心脏代谢蛋白的血浆水平进行了测量。使用Fisher精确检验分析分类变量,使用学生独立样本t检验或Welch t检验分析连续变量,以比较复发性中风患者和首次中风患者之间的差异。蛋白质分为全身蛋白和颅内蛋白,并以5.0%的错误发现率进行独立样本t检验。显著变量用于多因素逻辑回归分析。既往中风组有20例患者,首次中风组有121例患者。既往中风组女性比例显著更高(80.0%对50.4%,p = 0.016),高脂血症合并症发生率更低(10.5%对35.5%,p = 0.034)。既往中风患者中有两种全身蛋白显著更高:CCL14和FGF-19。多因素逻辑回归分析发现,CCL14和FGF-19水平较高可预测中风复发。连同其他人口统计学因素,这些蛋白质可为识别有复发性缺血性中风风险的患者提供预测模型。血清CCL14和FGF-19水平是易于获取的生物标志物,使其有可能成为预防复发性中风的治疗靶点。